Main menu

Predictive Biosciences this week said it has started two prospective studies to assess its bladder cancer assays following a successful pilot study.

The studies, each enrolling about 1,000 subjects in at least 10 clinical trial sites, will evaluate the Lexington, Mass.-based firm's Clinical Intervention Determining Diagnostic approach, which is based on high negative predictive value, or NPV, to identify patients who do not have recurring bladder cancer.

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.